In the late phase of cerebral ischemic injury, recovery is dependent on the restoration of the NVU complex
What to watch for: GI side effects often increase with this first dose bump
Discontinued formulations Efpeglenatide and taspoglutide Efpeglenatide and taspoglutide were once-promising, long-acting GLP-1 receptor agonists developed for the treatment of T2DM, both designed for once-weekly administration
Peptide molecules at this interface experience mechanical stress that can cause denaturation, essentially unfolding the protein structure and reducing biological activity
The most common side effects are dry mouth, insomnia (especially if taken too late in the day), increased heart rate, jitteriness or restlessness, and constipation
FACT 5 OF 6 Check methylmalonic acid (MMA) for early detection MMA is a more sensitive marker than serum B12